Pyridazin-3-ylboronic acid | 1175560-30-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: Pyridazin-3-ylboronic acid
• 英文别名: pyridazin-3-ylboronic acid
• CAS: 1175560-30-1
• 化学式: C₄H₅BN₂O₂
• 分子量: 123.907
• InChiKey: LRHOJUFCNKAYLN-UHFFFAOYSA-N

物化性质

• 沸点：
  418.3±37.0 °C(Predicted)
• 密度：
  1.33±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.84
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  66.2
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3,6-二氢-4-[[(三氟甲基)磺酰]氧基]-1(2H)-吡啶甲酸叔丁酯 、 Pyridazin-3-ylboronic acid 在 palladium catalyst 作用下， 生成
  参考文献：
  名称：

  Potent heteroarylpiperidine and carboxyphenylpiperidine 1-alkyl-cyclopentane carboxamide CCR2 antagonists

  摘要：

  This report describes replacement of the 4-(4-fluorophenyl)piperidine moiety in our CCR2 antagonists with 4-heteroaryl piperidine and 4-(carboxyphenyl)-piperidine subunits. Some of the resulting analogs retained potency in our CCR2 binding assay and had improved selectivity versus the I-Kr channel; poor selectivity against I-Kr had been a liability of earlier analogs in this series. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.12.029

文献信息

• Substituted uracil derivatives as potent inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1)
  作者：Henning Steinhagen、Michael Gerisch、Joachim Mittendorf、Karl-Heinz Schlemmer、Barbara Albrecht

  DOI：10.1016/s0960-894x(02)00602-9

  日期：2002.11

  A new class of PARP-1 inhibitors, namely substituted fused uracil derivatives were synthesised. Starting from a derivative with an IC(50)=2microM the chemical optimisation program led to compounds with more than a 100-fold increase in potency (IC(50)<20nM). Additionally, physicochemical and pharmacokinetic properties were evaluated. It could be shown that compounds bearing a piperazine or phenyl substituted

  合成了一类新的PARP-1抑制剂，即取代的稠合尿嘧啶衍生物。从IC（50）= 2microM的衍生物开始，化学优化程序导致化合物的效力增加了100倍以上（IC（50）<20nM）。另外，评估了理化和药代动力学性质。可以证明带有哌嗪或苯基取代的βAla-Gly侧链的化合物表现出最佳的整体性能。
• [EN] WNT PATHWAY MODULATORS<br/>[FR] MODULATEURS DE LA VOIE WNT
  申请人：AGENCY SCIENCE TECH & RES

  公开号：WO2015094119A1

  公开（公告）日：2015-06-25

  The present invention relates to dihydropyrazolo[l,5-a]pyrimidine compounds of formula I, defined herein, as WNT pathways modulators, processes for making them, and pharmaceutical compositions comprising them. Methods of treatment of conditions mediated by WNT pathway signalling including cancer, fibrosis, stem cell and diabetic retinopathy, rheumatoid arthritis, psoriasis and myocardial infarction, comprising the compounds of formula I are also provided.

  本发明涉及式I的二氢吡唑并[1,5-a]嘧啶化合物，其在此处定义为WNT通路调节剂，以及制备它们的方法和包含它们的药物组合物。还提供了使用式I化合物治疗通过WNT通路信号传导介导的疾病的方法，包括癌症、纤维化、干细胞和糖尿病性视网膜病变、类风湿性关节炎、牛皮癣和心肌梗死。
• Potent heteroarylpiperidine and carboxyphenylpiperidine 1-alkyl-cyclopentane carboxamide CCR2 antagonists
  作者：Alexander Pasternak、Stephen D. Goble、Pasquale P. Vicario、Jerry Di Salvo、Julia M. Ayala、Mary Struthers、Julie A. DeMartino、Sander G. Mills、Lihu Yang

  DOI：10.1016/j.bmcl.2007.12.029

  日期：2008.2

  This report describes replacement of the 4-(4-fluorophenyl)piperidine moiety in our CCR2 antagonists with 4-heteroaryl piperidine and 4-(carboxyphenyl)-piperidine subunits. Some of the resulting analogs retained potency in our CCR2 binding assay and had improved selectivity versus the I-Kr channel; poor selectivity against I-Kr had been a liability of earlier analogs in this series. (C) 2007 Elsevier Ltd. All rights reserved.